God  our Guide 
cidpUSA Foundation




Pork plant controversy

Eliminate insulin implants

Sugar treatment


irregular periods

Myasthenia diet

Wagner's syndrome

weakness myopathy

cancer survivor

CIDP info
Diet anti-inflammatory
Burning  Feet Home
Services Page
Chronic Fatigue
Autoimmune diseases
Bible healing
Celiac disease
Natural Makeup
Neck Pain
Ocular diseases
Chronic fatigue syndrome
Women Heart Attacks
Cure all diseases
Memory problems
Breast Lymph Drainage
Kidney stone Buster
Bras in breast cancer
Skin repair Clinic

CIDP articles


Multi Focal Motor neuropathy


Lewis Summer

Tips for CIDP

Axonal EMG


Dr Katz -CIDP






     Quranic Shifa


 inflammatory and paraproteinemic neuropathies CIDPUSA-Autoimmune diseases

         Guide to natural treatment of all diseases Flame within E-book. 
      contact through services link    


Treatment of inflammatory and paraproteinemic neuropathies.

Monaco S, Turri E, Zanusso G, Maistrello B.

Section of Clinical Neurology, Department of Neurological and Visual Sciences, University of Verona, Verona, Italy.

Acquired demyelinating and inflammatory neuropathies encompass a number of acute and chronic autoimmune conditions characterized by variable degrees of clinical involvement. These disorders, including Guillain-Barre syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), and paraprotein-associated neuropathy, have an overall annual incidence of 2-4/100,000 worldwide and are potentially treatable. Over the last few years, several investigations have helped clarify the pathogenesis of immune neuropathies and the definition of molecular targets involved in these diseases, thus providing firmer grounds for treatment with classical immunosuppressive drugs and new biological agents. In GBS and related variants, which are characterized by cellular inflammation and alterations of the blood-nerve barrier, randomized clinical trials show that plasma exchange (PE) and intravenous immunoglobulin (IVIg) are equally effective as disease-modifying treatments, although IVIg has been adopted as the favourite treatment in most centres. In CIDP, controlled clinical trials have established the efficacy of oral prednisone, PE and IVIg, with intermittent IVIg treatment or corticosteroids being usually preferred. Adding azathioprine can help keep lower the required dose of prednisone, while other immunosuppressive agents, such as cyclophosphamide and cyclosporin A may have side effects, limiting their use to selected cases. Currently, the efficacy of interferon beta and alfa is under evaluation. Controlled trials support the view that IVIg is the treatment of choice in MMN. Patients resistant to IVIg administration may benefit of treatments which deplete B cells, such as cyclophosphamide and rituximab. Demyelinating neuropathies associated with circulating paraproteins are clinically heterogeneous, depending on the reactivity and type of the monoclonal (M) protein. In many cases, neuropathies associated with IgM M proteins are not treated because of their slow progression. In patients with a disabling or rapid progression, small trials have shown short-term benefits from IVIg or PE. Recently, fludarabine and rituximab have been reported as beneficial in selected cases.

Cur Drug Targets Immune Endocr Metabol Disord. 2004 Jun;4(2):141-8.
Publication Types:
Review, Tutorial

PMID: 15180454 [PubMed - indexed for MEDLINE]


Treatment of alcoholic poly neuropathy

     want to learn about the brain and spinal cord


Tomato as a medicine

Immune deficiency  

Prevent Osteoporosis

 Some rheumatic disorders


Celiac disease

What is diabetes?